Skip to main content
. 2012 Apr 16;16(4):765–775. doi: 10.1111/j.1582-4934.2011.01380.x

Fig 5.

Fig 5

Pre-treatment CLDN5 mRNA levels are significantly lower in patients defined as ‘good responders’ to IFN-β treatment. The relative expression of CLDN5 RNA (2ΔCT) was determined by real-time RT-PCR in PBLs collected from patients defined as ‘good responders’ (n = 13) and ‘others’ –patients whose clinical response to IFN-β did not meet the criteria for ‘good responders’ (n = 9), before and after 3–6 months of IFN-β treatment.